In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates

  • 1.

    Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).

    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 2.

    Zetsche, B. et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 163, 759–771 (2015).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 3.

    Strecker, J. et al. Engineering of CRISPR–Cas12b for human genome editing. Nat. Commun. 10, 212 (2019).

    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 4.

    Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420–424 (2016).

    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 5.

    Gaudelli, N. M. et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature 551, 464–471 (2017).

    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 6.

    Doudna, J. A. The promise and challenge of therapeutic genome editing. Nature 578, 229–236 (2020).

    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 7.

    GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1736–1788 (2018).


    Google Scholar
     

  • 8.

    Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149–157 (2019).

    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 9.

    Yin, H. et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32, 551–553 (2014).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 10.

    Ding, Q. et al. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ. Res. 115, 488–492 (2014).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 11.

    Yin, H. et al. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat. Biotechnol. 35, 1179–1187 (2017).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 12.

    Finn, J. D. et al. A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 22, 2227–2235 (2018).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 13.

    Chadwick, A. C., Wang, X. & Musunuru, K. In vivo base editing of PCSK9 (proprotein convertase subtilisin/kexin type 9) as a therapeutic alternative to genome editing. Arterioscler. Thromb. Vasc. Biol. 37, 1741–1747 (2017).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 14.

    Ryu, S. M. et al. Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy. Nat. Biotechnol. 36, 536–539 (2018).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 15.

    Rossidis, A. C. et al. In utero CRISPR-mediated therapeutic editing of metabolic genes. Nat. Med. 24, 1513–1518 (2018).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 16.

    Abifadel, M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154–156 (2003).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 17.

    Cohen, J. C., Boerwinkle, E., Mosley, T. H., Jr & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264–1272 (2006).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 18.

    Rao, A. S. et al. Large-scale phenome-wide association study of PCSK9 variants demonstrates protection against ischemic stroke. Circ. Genom. Precis. Med. 11, e002162 (2018).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 19.

    Zhao, Z. et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79, 514–523 (2006).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 20.

    Hooper, A. J., Marais, A. D., Tanyanyiwa, D. M. & Burnett, J. R. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a southern African population. Atherosclerosis 193, 445–448 (2007).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 21.

    Ray, K. K. et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N. Engl. J. Med. 376, 1430–1440 (2017).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 22.

    Brandts, J. & Ray, K. K. Low density lipoprotein cholesterol-lowering strategies and population health: time to move to a cumulative exposure model. Circulation 141, 873–876 (2020).

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 23.

    Choudhry, N. K. et al. Full coverage for preventive medications after myocardial infarction. N. Engl. J. Med. 365, 2088–2097 (2011).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 24.

    Rodriguez, F. et al. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 4, 206–213 (2019).

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 25.

    Hines, D. M., Rane, P., Patel, J., Harrison, D. J. & Wade, R. L. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors. Vasc. Health Risk Manag. 14, 409–418 (2018).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 26.

    Zafrir, B., Egbaria, A., Stein, N., Elis, A. & Saliba, W. PCSK9 inhibition in clinical practice: treatment patterns and attainment of lipid goals in a large health maintenance organization. J. Clin. Lipidol. 15, 202–211.e2 (2021).

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 27.

    Gaudelli, N. M. et al. Directed evolution of adenine base editors with increased activity and therapeutic application. Nat. Biotechnol. 38, 892–900 (2020).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 28.

    Hendel, A. et al. Chemically modified guide RNAs enhance CRISPR–Cas genome editing in human primary cells. Nat. Biotechnol. 33, 985–989 (2015).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 29.

    Conway, A. et al. Non-viral delivery of zinc finger nuclease mRNA enables highly efficient in vivo genome editing of multiple therapeutic gene targets. Mol. Ther. 27, 866–877 (2019).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 30.

    Villiger, L. et al. In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA. Nat. Biomed. Eng. 5, 179–189 (2021).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 31.

    Petri, K. et al. Global-scale CRISPR gene editor specificity profiling by ONE-seq identifies population-specific, variant off-target effects. Preprint at https://doi.org/10.1101/2021.04.05.438458 (2021).

  • 32.

    Liang, P. et al. Genome-wide profiling of adenine base editor specificity by EndoV-seq. Nat. Commun. 10, 67 (2019).

    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 33.

    Kim, D., Kim, D. E., Lee, G., Cho, S. I. & Kim, J. S. Genome-wide target specificity of CRISPR RNA-guided adenine base editors. Nat. Biotechnol. 37, 430–435 (2019).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 34.

    Grünewald, J. et al. Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors. Nature 569, 433–437 (2019).

    ADS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 35.

    Zhou, C. et al. Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis. Nature 571, 275–278 (2019).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 36.

    Wang, L. et al. Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9. Mol. Therhttps://doi.org/10.1016/j.ymthe.2021.02.020 (2021).

  • 37.

    Villiger, L. et al. Treatment of a metabolic liver disease by in vivo genome base editing in adult mice. Nat. Med. 24, 1519–1525 (2018).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 38.

    Song, C. Q. et al. Adenine base editing in an adult mouse model of tyrosinaemia. Nat. Biomed. Eng. 4, 125–130 (2020).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 39.

    Koblan, L. W. et al. In vivo base editing rescues Hutchinson–Gilford progeria syndrome in mice. Nature 589, 608–614 (2021).

    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 40.

    Clement, K. et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat. Biotechnol. 37, 224–226 (2019).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 41.

    Magoč, T. & Salzberg, S. L. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics 27, 2957–2963 (2011).

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 42.

    Concordet, J. P. & Haeussler, M. CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens. Nucleic Acids Res. 46, W242–W245 (2018).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 43.

    Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinformatics 43, 11.10.1–11.10.33 (2013).


    Google Scholar
     

  • 44.

    Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).

    CAS 

    Google Scholar
     

  • 45.

    Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 46.

    Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).

    CAS 
    Article 

    Google Scholar
     

  • 47.

    Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 48.

    Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).

    Article 

    Google Scholar
     

  • 49.

    Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841–842 (2010).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 50.

    Bae, S., Park, J. & Kim, J. S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473–1475 (2014).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar